BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 14681681)

  • 1. Activating BRAF and N-Ras mutations in sporadic primary melanomas: an inverse association with allelic loss on chromosome 9.
    Kumar R; Angelini S; Hemminki K
    Oncogene; 2003 Dec; 22(58):9217-24. PubMed ID: 14681681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRAF mutations in metastatic melanoma: a possible association with clinical outcome.
    Kumar R; Angelini S; Czene K; Sauroja I; Hahka-Kemppinen M; Pyrhönen S; Hemminki K
    Clin Cancer Res; 2003 Aug; 9(9):3362-8. PubMed ID: 12960123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression.
    Omholt K; Karsberg S; Platz A; Kanter L; Ringborg U; Hansson J
    Clin Cancer Res; 2002 Nov; 8(11):3468-74. PubMed ID: 12429636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p16INK4a inactivation is not frequent in uncultured sporadic primary cutaneous melanoma.
    Fujimoto A; Morita R; Hatta N; Takehara K; Takata M
    Oncogene; 1999 Apr; 18(15):2527-32. PubMed ID: 10229204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel N-ras mutation in malignant melanoma is associated with excellent prognosis.
    Demunter A; Ahmadian MR; Libbrecht L; Stas M; Baens M; Scheffzek K; Degreef H; De Wolf-Peeters C; van Den Oord JJ
    Cancer Res; 2001 Jun; 61(12):4916-22. PubMed ID: 11406571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for three tumor suppressor loci on chromosome 9p involved in melanoma development.
    Pollock PM; Welch J; Hayward NK
    Cancer Res; 2001 Feb; 61(3):1154-61. PubMed ID: 11221846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Status of the DPC4 tumor suppressor gene in sporadic colon adenocarcinoma of Croatian patients: identification of a novel somatic mutation.
    Popović Hadzija M; Radosevic S; Kovacević D; Lukac J; Hadzija M; Spaventi R; Pavelić K; Kapitanović S
    Mutat Res; 2004 Apr; 548(1-2):61-73. PubMed ID: 15063137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53 mutations in human cutaneous melanoma correlate with sun exposure but are not always involved in melanomagenesis.
    Zerp SF; van Elsas A; Peltenburg LT; Schrier PI
    Br J Cancer; 1999 Feb; 79(5-6):921-6. PubMed ID: 10070891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High sensitivity scanning of colorectal tumors and matched plasma DNA for mutations in APC, TP53, K-RAS, and BRAF genes with a novel DHPLC fluorescence detection platform.
    Lilleberg SL; Durocher J; Sanders C; Walters K; Culver K
    Ann N Y Acad Sci; 2004 Jun; 1022():250-6. PubMed ID: 15251969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression.
    Omholt K; Platz A; Kanter L; Ringborg U; Hansson J
    Clin Cancer Res; 2003 Dec; 9(17):6483-8. PubMed ID: 14695152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of the role of the ras protooncogene point mutation in human uveal melanomas.
    Soparker CN; O'Brien JM; Albert DM
    Invest Ophthalmol Vis Sci; 1993 Jun; 34(7):2203-9. PubMed ID: 8505202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Analysis, identification and correction of some errors of model refseqs appeared in NCBI Human Gene Database by in silico cloning and experimental verification of novel human genes].
    Zhang DL; Ji L; Li YD
    Yi Chuan Xue Bao; 2004 May; 31(5):431-43. PubMed ID: 15478601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 and RAS gene mutations in multiple myeloma.
    Portier M; Molès JP; Mazars GR; Jeanteur P; Bataille R; Klein B; Theillet C
    Oncogene; 1992 Dec; 7(12):2539-43. PubMed ID: 1461658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutation of H-ras is infrequent in bladder cancer: confirmation by single-strand conformation polymorphism analysis, designed restriction fragment length polymorphisms, and direct sequencing.
    Knowles MA; Williamson M
    Cancer Res; 1993 Jan; 53(1):133-9. PubMed ID: 8093230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CDKN2A mutation and deletion status in thin and thick primary melanoma.
    Cachia AR; Indsto JO; McLaren KM; Mann GJ; Arends MJ
    Clin Cancer Res; 2000 Sep; 6(9):3511-5. PubMed ID: 10999737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of heterozygosity in the MXI1 gene is a frequent occurrence in melanoma.
    Ariyanayagam-Baksh SM; Baksh FK; Swalsky PA; Finkelstein SD
    Mod Pathol; 2003 Oct; 16(10):992-5. PubMed ID: 14559981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas.
    Hashemi J; Platz A; Ueno T; Stierner U; Ringborg U; Hansson J
    Cancer Res; 2000 Dec; 60(24):6864-7. PubMed ID: 11156381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of heterozygosity for chromosome region 11p15 in Wilms' tumours is not related to HRAS gene transforming mutations.
    Baird P; Wadey R; Cowell J
    Oncogene; 1991 Jul; 6(7):1147-9. PubMed ID: 1861864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of mutations of neurofibromatosis type 1 gene and N-ras gene in acute myelogenous leukemia.
    Lee YY; Kim WS; Bang YJ; Jung CW; Park S; Yoon WJ; Cho KS; Kim IS; Jung TJ; Choi IY
    Stem Cells; 1995 Sep; 13(5):556-63. PubMed ID: 8528106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues.
    Gorden A; Osman I; Gai W; He D; Huang W; Davidson A; Houghton AN; Busam K; Polsky D
    Cancer Res; 2003 Jul; 63(14):3955-7. PubMed ID: 12873990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.